Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W1SJ | ISIN: US29664W1053 | Ticker-Symbol: 0ET
Tradegate
22.07.25 | 19:48
1,041 Euro
-0,14 % -0,002
1-Jahres-Chart
ESPERION THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ESPERION THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0101,05022.07.
1,0151,07022.07.

Aktuelle News zur ESPERION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEsperion Therapeutics, Inc.: Esperion to Report Second Quarter 2025 Financial Results on August 52
08.07.Esperion settles litigation with Accord Healthcare11
08.07.Esperion Therapeutics, Inc.: Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040180ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the...
► Artikel lesen
01.07.Esperion Therapeutics, Inc. - 8-K, Current Report3
01.07.Esperion Therapeutics, Inc.: Esperion Appoints Craig Thompson to Board of Directors7
13.06.Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential27
ESPERION Aktie jetzt für 0€ handeln
09.06.Esperion bei Goldman Sachs Konferenz: Weg zur Profitabilität40
02.06.Esperion Therapeutics, Inc. - 8-K, Current Report10
14.05.Cascale Talks ESPR at Innovation Forum Sustainable Apparel Event in Amsterdam372NORTHAMPTON, MA / ACCESS Newswire / May 14, 2025 / Elisabeth von Reitzenstein, senior director of policy and public affairs at Cascale, recently took to the stage at Innovation Forum's Sustainable Apparel...
► Artikel lesen
12.05.Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol8
12.05.Esperion Therapeutics, Inc.: Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) Prior to April 19, 2040267ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited...
► Artikel lesen
09.05.HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines10
08.05.Esperion Therapeutics, Inc.: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)187ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's...
► Artikel lesen
08.05.HLS Therapeutics Inc: HLS Therapeutics forms partnership with Esperion4
08.05.Esperion and HLS partner to commercialize heart disease treatments in Canada5
08.05.Esperion Therapeutics, Inc. - 10-Q, Quarterly Report12
08.05.HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL and NEXLIZET in Canada5
08.05.Esperion Therapeutics, Inc.: Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Canada12
07.05.ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down20
06.05.Esperion Q1 2025 slides: U.S. product sales surge 41% amid strategic expansion27
Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3